{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:27:44Z","timestamp":1790674064905,"version":"4.1.0"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00990","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T04:26:40Z","timestamp":1557203200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":114,"title":["Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Chune","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","volume-title":"Cancer Facts and Figures 2018.","author":"Society","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-med-050410-105655","article-title":"Targeting metastatic melanoma","volume":"63","author":"Flaherty","year":"2012","journal-title":"Ann Rev Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1600-0463.2007.apm_855.xml.x","article-title":"The genome and epigenome of malignant melanoma","volume":"115","author":"Dahl","year":"2007","journal-title":"APMIS."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene."},{"key":"B7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature."},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Molecul Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/jid.2009.334","article-title":"KIT as a therapeutic target in melanoma","volume":"130","author":"Garrido","year":"2010","journal-title":"J Invest Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene."},{"key":"B16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"key":"B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.molcel.2008.12.026","article-title":"Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation","volume":"33","author":"Zheng","year":"2009","journal-title":"Mol Cell."},{"key":"B18","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma","volume":"63","author":"Dong","year":"2003","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell."},{"key":"B26","doi-asserted-by":"publisher","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature."},{"key":"B28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur J Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann Transl Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: first global approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMc1209663","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/S1470-2045(14)71023-X","article-title":"Vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"15","author":"Rahman","year":"2014","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature."},{"key":"B38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFR\u03b2-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"B44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","article-title":"A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/onc.2011.250","article-title":"Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF","volume":"31","author":"Xing","year":"2012","journal-title":"Oncogene."},{"key":"B47","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.yasu.2011.04.003","article-title":"Immunotherapy for metastatic solid cancers","volume":"45","author":"Turcotte","year":"2011","journal-title":"Adv Surgery."},{"key":"B49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp Mol Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/369327a0","article-title":"Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling","volume":"369","author":"Pages","year":"1994","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell."},{"key":"B53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science."},{"key":"B56","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/0008-5472.CAN-17-1615","article-title":"Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4","volume":"78","author":"Mo","year":"2018","journal-title":"Cancer Re."},{"key":"B57","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13578-018-0229-z","article-title":"Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?","volume":"8","author":"Tang","year":"2018","journal-title":"Cell Biosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science."},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.TARG-13-B290","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"B67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMc1509660","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"B73","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B74","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity."},{"key":"B75","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1056\/NEJMc1812500","article-title":"Nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Mansouri","year":"2018","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ajco.13100","article-title":"Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma","volume":"15","author":"Parakh","year":"2019","journal-title":"Asia Pac J Clin Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"E8698","DOI":"10.1073\/pnas.1809232115","article-title":"Adjuvant effect of the novel TLR1\/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"2010","journal-title":"Eur J Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/jid.2014.29","article-title":"Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3","volume":"134","author":"Camisaschi","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2741\/e414","article-title":"Blocking IDO activity to enhance anti-tumor immunity","volume":"4","author":"Munn","year":"2012","journal-title":"Front Biosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J Clin Invest."},{"key":"B93","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e6910","DOI":"10.1371\/journal.pone.0006910","article-title":"The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase","volume":"4","author":"Sorensen","year":"2009","journal-title":"PLoS ONE."},{"key":"B96","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2018","journal-title":"Semin Immunopathol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J Immunol Methods."},{"key":"B98","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Molecul Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12032-018-1149-9","article-title":"Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors","volume":"35","author":"Jindal","year":"2018","journal-title":"Med Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/imt.11.45","article-title":"Immunomodulatory cytokines as therapeutic agents for melanoma","volume":"3","author":"Nicholas","year":"2011","journal-title":"Immunotherapy."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/jps.21596","article-title":"Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy","volume":"98","author":"Shaker","year":"2009","journal-title":"J Pharmac Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/CJI.0000000000000149","article-title":"Clinical response rates from interleukin-2 therapy for metastatic melanoma over 30 years' experience: a meta-analysis of 3312 patients","volume":"40","author":"Bright","year":"2017","journal-title":"J Immunother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/eji.200323600","article-title":"Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1","volume":"33","author":"Kubsch","year":"2003","journal-title":"Eur J Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signal."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology."},{"key":"B114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy","volume":"110","author":"Suciu","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B116","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1684\/ejd.2017.3169","article-title":"A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy","volume":"28","author":"Fukumoto","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab plus pegylated interferon alfa-2b or Ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/CMR.0000000000000435","article-title":"STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-\u03b1","volume":"28","author":"Machiraju","year":"2018","journal-title":"Melanoma Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/978-3-319-22539-5_16","article-title":"Novel treatments in development for melanoma","volume":"167","author":"Bernatchez","year":"2016","journal-title":"Cancer Treat Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"B121","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"key":"B122","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.immuni.2017.08.001","article-title":"Making it personal: neoantigen vaccines in metastatic melanoma","volume":"47","author":"Hellmann","year":"2017","journal-title":"Immunity."},{"key":"B123","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.1103822","article-title":"Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence","volume":"189","author":"Jensen","year":"2012","journal-title":"J Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","article-title":"BRAFV600E Co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma","volume":"3","author":"Bradley","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","article-title":"Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression","volume":"4","author":"Kono","year":"2006","journal-title":"Molecul Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat Commun."},{"key":"B134","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/pcmr.12098","article-title":"Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression","volume":"26","author":"Long","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK Inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","article-title":"BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy","volume":"72","author":"Koya","year":"2012","journal-title":"Cancer Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","article-title":"Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties","volume":"62","author":"Ott","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B139","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V96.3.1039","article-title":"The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells","volume":"96","author":"Ardeshna","year":"2000","journal-title":"Blood."},{"key":"B140","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0181","article-title":"MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells","volume":"2","author":"Vella","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell."},{"key":"B142","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature."},{"key":"B143","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1158\/0008-5472.CAN-14-1339","article-title":"Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma","volume":"74","author":"Ferrari de Andrade","year":"2014","journal-title":"Cancer Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/2326-6066.CIR-16-0380","article-title":"Shifting the balance of activating and inhibitory natural killer receptor ligands on BRAF(V600E) melanoma lines with vemurafenib","volume":"5","author":"Frazao","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-10-1911","article-title":"The oncogenic BRAF kinase inhibitor PLX4032\/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations","volume":"16","author":"Comin-Anduix","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-13-0160","article-title":"Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor","volume":"2","author":"Callahan","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15","article-title":"CA184-161: a phase I\/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma","author":"Ribas","year":"2012","journal-title":"J Clin Oncol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/pcmr.12383","article-title":"Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab","volume":"28","author":"Minor","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e1423172","DOI":"10.1080\/2162402X.2017.1423172","article-title":"A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma","volume":"7","author":"Mooradian","year":"2018","journal-title":"Oncoimmunology."},{"key":"B154","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-018-0387-x","article-title":"A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma","volume":"6","author":"Clark","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B155","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1078-0432.CCR-16-0906","article-title":"A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma","volume":"23","author":"Deniger","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/2326-6066.CIR-14-0074","article-title":"BRAF inhibition alleviates immune suppression in murine autochthonous melanoma","volume":"2","author":"Steinberg","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236","article-title":"Host immunity contributes to the anti-melanoma activity of BRAF inhibitors","volume":"123","author":"Knight","year":"2013","journal-title":"J Clin Invest."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","article-title":"Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes","volume":"100","author":"Alfaro","year":"2009","journal-title":"Br J Cancer."},{"key":"B159","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF\u03b1","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov."},{"key":"B161","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-Induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/0008-5472.CAN-16-1755","article-title":"Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors","volume":"77","author":"Steinberg","year":"2017","journal-title":"Cancer Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e1052212","DOI":"10.1080\/2162402X.2015.1052212","article-title":"Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma","volume":"5","author":"Homet Moreno","year":"2016","journal-title":"Oncoimmunology."},{"key":"B166","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbrc.2017.01.128","article-title":"Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma","volume":"484","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15","article-title":"Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma","author":"Ribas","year":"2015","journal-title":"J Clin Oncol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"djv435","DOI":"10.1093\/jnci\/djv435","article-title":"Antitumor activity of BRAF inhibitor and IFN\u03b1 combination in BRAF-mutant melanoma","volume":"108","author":"Sabbatino","year":"2016","journal-title":"J Natl Cancer Inst."},{"key":"B169","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CMR.0000000000000444","article-title":"Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors","volume":"28","author":"Chesney","year":"2018","journal-title":"Melanoma Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11912-016-0531-z","article-title":"Influences of BRAF inhibitors on the immune microenvironment and the rationale for combined molecular and immune targeted therapy","volume":"18","author":"Reddy","year":"2016","journal-title":"Curr Oncol Rep."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/2159-8290.CD-14-0477","article-title":"Universes collide: combining immunotherapy with targeted therapy for cancer","volume":"4","author":"Wargo","year":"2014","journal-title":"Cancer Discov."},{"key":"B172","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science."},{"key":"B173","doi-asserted-by":"publisher","first-page":"molcanther","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Molecul Cancer Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2340\/00015555-2748","article-title":"Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients","volume":"97","author":"Ashida","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"e1277305","DOI":"10.1080\/2162402X.2016.1277305","article-title":"Tumor-infiltrating CD39(+)gammadeltaTregs are novel immunosuppressive T cells in human colorectal cancer","volume":"6","author":"Hu","year":"2017","journal-title":"Oncoimmunology."},{"key":"B180","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating cd8(+) T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res."},{"key":"B181","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B182","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00990\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,24]],"date-time":"2019-11-24T18:06:24Z","timestamp":1574618784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00990\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":182,"alternative-id":["10.3389\/fimmu.2019.00990"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00990","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"article-number":"990"}}